Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene

Human Gene Therapy

Volumn 7, Issue 2, 1996, Pages 141-148

  Elshami, Ashraf A ^a   Kucharczuk, John C ^a   Zhang, Hong Bing ^a   Smythe, W Roy ^a   Hwang, Harry C ^a   Litzky, Leslie A ^a   Kaiser, Larry R ^a   Albelda, Steven M ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE TRANSFER; HERPES SIMPLEX VIRUS; IMMUNOCOMPETENCE; INTRAPERITONEAL DRUG ADMINISTRATION; MALIGNANT MESOTHELIOMA; NONHUMAN; PLEURA CAVITY; PLEURA MESOTHELIOMA; RAT; SURVIVAL; TUMOR REGRESSION; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA; HERPES; SIMPLEXVIRUS;

EID: 0030046154     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.2-141     Document Type: Article

References (26)

1. ALLEY, M.C., SCUDIERO, D.A., MONKS, A., HURSEY, M.L., CZERWINSKI, M.J., and FINE, L.F. (1988). Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48, 589-601.
2. ANTMAN, K.H. (1993). Natural history and epidemiology of malignant mesothelioma. Chest 103, 373S-376S.
3. BERKNER, K.L. (1988). Development of adenovirus vectors for the expression of heterologous genes. Biotechniques 6, 616-629.
4. BRODY, S.L., JAFFE, H.A., HAN, S.K., WERSTO, R.P., and CRYSTAL, R.G. (1994). Direct in vivo gene transfer and expression in malignant cells using adenovirus vectors. Hum. Gene Ther. 5, 437-447.
5. CHEN, S-H., SHINE, H.D., GOODMAN, J.C., GROSSMAN, R.G., and WOO, S.L.C. (1994). Gene therapy for brain rumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA 91, 3054-3057.
6. CLINICAL PROTOCOLS. Cancer Gene Ther. (1994). 1, 289-295.
7. CRAIGHEAD, J.E., AKLEY, N.J., GOULD, L.B., and LIBBUS, B.G. (1987). Characteristics of tumors and tumor cells cultured from experimental asbestos-induced mesotheliomas in rats. Am. J. Pathol. 129, 448-462.
8. CULVER, K.W., RAM, Z., WALLBRIDGE, S., ISHII, H., OLDFIELD, E.H., and BLAESE, R.M. (1992). In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256, 1550-1552.
9. ENGLEHARDT, J.F., YANG, Y., STRATFORD-PERRICAUDET, L.D., ALLEN, E.D., KOZARSKY, K., PERICAUDET, M., YANKASKAS, J.R., and WILSON, J.M. (1993). Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. Nature Genet. 4, 27-34.
10. ENGLEHARDT, J.F., YE, X., DORANZ, B., and WILSON, J.M. (1994). Ablation of E2a in recombinant adenoviruses improves transgene persistence and decreases immune response in mouse liver. Proc. Natl. Acad. Sci. USA 91, 6196-6200.
11. FREEMAN, S.M., ABBOUD, C.N., WHARTENBY, K.A., PACKMAN, C.H., KOEPLIN, D.S., MOOLTEN, F.L., and ABRAHAM, G.N. (1993). The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53, 5274-5283.
12. HWANG, H.C., SMYTHE, W.R., ELSHAMI, A.A., AMIN, K.M., WILLIAMS, J., LITZKY, L.A., KAISER, L.R., and ALBELDA, S.M. (1995). Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am. J. Respir. Cell Mol. Biol. 13, 7-16.
13. KUCHARCZUK, J.C., ELSHAMI, A.A., ZHANG, H.B., SMYTHE, W.R., HWANG, H.C., TOMLINSON, J.S., AMIN, K.M., LITZKY, L.A., ALBELDA, S.M., and KAISER, L.R. (1995). Development of an intrapleural model of mesothelioma in an immune competent animal to study adenoviral mediated gene transfer. Ann. Thor. Surg. 60, 593-598.
14. MATTHEWS, T., and BOEHME, R. (1988). Antiviral activity and mechanism of action of ganciclovir. Rev. Infect. Dis. 10, S490-S494.
15. MOOLTEN, F.L. (1994). Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther. 1, 279-287.
16. MOOLTEN, F.L., and WELLS, J.M. (1990). Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Canc. Inst. 82, 297-300.
17. RAM, Z., CULVER, K.W., WALLBRIDGE, S., BLAESE, R.M., and OLDFIELD, E.H. (1993). In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53, 83-88.
18. RUSCH, V.W. (1993). Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma. Chest 103, 382S-384S.
19. SAMBROOK, J., FRITSCH, E.F., and MANIATIS, T. (1989). Molecular Cloning: A Laboratory Manual. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).
20. SETOGUCHI, Y., JAFFE, H.A., CHUM, C-S., and CRYSTAL, R.G. (1994). Intraperitoneal in vivo gene therapy to deliver alpha-1-antitrypsin to the systemic circulation. Am. J. Respir. Cell. Mol. Biol. 10, 369-377.
21. SMYTHE, W.R., KAISER, L.R., AMIN, K.M., PILEWSKI, J.M., ECK, S., WILSON, J.M., and ALBELDA, S.M. (1994a). Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann. Thor. Surg. 57, 1395-1401.
22. SMYTHE, W.R., HWANG, H.C., AMIN, K.M., ECK, S.L., DAVIDSON, B.L., WILSON, J.M., KAISER, L.R., and ALBELDA, S.M. (1994b). Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: An effective in vitro drug sensitization system. Cancer Res. 54, 2055-2059.
23. SMYTHE, W.R., HWANG, H.C., ELSHAMI, A., AMIN, K.M., ECK, S.L., DAVIDSON, B.L., WILSON, J.M., KAISER, L.R., and ALBELDA, S.M. (1995). Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann. Surg. 222, 78-86.
24. TAPSCOTT, S.J., MILLER, A.D., OLSON, J.M., BERGER, M.S., GROUDINE, M., and SPENCE, A.M. (1994). Gene therapy of the 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc. Natl. Acad. Sci. USA 91, 8185-8189.
25. YANG, Y., NUNES, F.A., BERENCSI, K., FURTH, E.E., GÖNCZÖL, E., and WILSON, J.M. (1994a). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91, 4407-4411.
26. YANG, Y., NUNES, F.A., BERENCSI, K., GÖNCZÖL, E., ENGLEHARDT, J.F., and WILSON, J.M. (1994b). Inactivation of E2a in recombinant adenovirus improves prospects for gene therapy in cystic fibrosis. Nature Genet. 7, 362-369.